Search for a command to run...
Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common inherited enzyme deficiency. It is a risk factor for kernicterus (i.e., bilirubin induced neurological damage) in jaundiced newborns and hemolysis following oxidant stress exposure. In June 2022, New York State (NYS) mandated hospitals to provide newborn screening for G6PD deficiency by a quantitative enzyme method or gene sequencing for newborns with certain clinical presentations, however since most hospital laboratories do not offer quantitative enzyme testing, samples are sent to reference laboratories. Reference laboratory turnaround time (TAT) is not optimal for making urgent clinical decisions for treating jaundice and providing results prior to newborn discharge. The Baebies FINDER G6PD Test (FINDER G6PD) provides G6PD enzyme activity values within 17 minutes using 50 µL of whole blood, providing timely results for all patients. Methods Validation of FINDER G6PD included intra-run precision studies with 20 runs of 2 levels of quality control (QC), and establishing a reference range by testing 120 healthy individuals. TAT, the time from sample collection to result reporting, and the prevalence of G6PD deficiency in the patient population were determined for two 6-month intervals: December 1, 2023 – May 31, 2024 when samples were sent to the reference laboratory and July 1, 2024 – December 31, 2024, when samples were tested in the hospital laboratory with FINDER G6PD. Results Intra-run precision performed with normal level QC demonstrated a mean of 12.7 U/gHb, standard deviation (SD) of 0.47, and a coefficient of variation (CV) of 3.7%. Intra-run precision performed with the abnormal (low) QC demonstrated a mean of 5.6 U/gHb, SD of 0.18, and CV of 3.3%. A total of 120 individuals, 62 females, and 58 males, were recruited for the reference range study, however, 2 samples were excluded because they demonstrated deficiency. Based on the remaining 118 samples, the reference interval was determined to be 8.0 U/gHb – 15.2 U/gHb using the transformed parametric method in EP Evaluator. The median TAT for reference laboratory testing was 75.4 hours (3.1 days) compared to 4.5 hours (0.2 days) for FINDER G6PD in-hospital laboratory testing. The prevalence of G6PD deficiency, defined as a test result below the reference range, was 15.5% (43/277) for all patients tested and 11.1% (2/18) for newborns (i.e., patients <=1 month) in reference laboratory testing and 17.9% (43/240) for all patients tested and 14.3% (3/21) for newborns in FINDER G6PD in-hospital laboratory testing. Conclusion The prevalence of G6PD deficiency in the population served by New York Presbyterian Hospital-Columbia University Irving Medical Center is high, demonstrating the need for G6PD testing results for patient care. Hospital laboratory testing using FINDER G6PD provides results in 4.5 hours compared to 3.1 days ensuring G6PD diagnosis prior to hospital discharge of newborns. This rapid TAT enables real-time decision-making allowing timely interventions, including treatment and education for G6PD-deficient newborns. Other patients, such as those being evaluated for possible treatment with medications contraindicated in individuals with G6PD deficiency (e.g., rasburicase), also benefit from more rapid testing results.